

State of Oklahoma
Oklahoma Health Care Authority
Spinraza™ (Nusinersen) Prior Authorization Form

Member Name: _____ **Date of Birth:** _____ **Member ID#:** _____

Drug Information

Physician billing (HCPCS code: _____) **Start Date (or date of next dose):** _____
Dose: _____ **Regimen:** _____

Billing Provider Information

SoonerCare Provider ID: _____ **Provider Name:** _____
Provider Phone: _____ **Provider Fax:** _____

Prescriber Information

Prescriber NPI: _____ **Prescriber Name:** _____
Prescriber Phone: _____ **Prescriber Fax:** _____ **Specialty:** _____

Criteria

For Initial Authorization (Initial approval will be for the duration of 6 months):

- Has the member previously been treated with Spinraza™ (nusinersen)? Yes ___ No ___
A. If member has previously received nusinersen, please provide dates of previous doses: _____
- What is the member's diagnosis?
 Spinal Muscular Atrophy (SMA)
A. What type of SMA does the member have (0-4)? _____
B. Does member currently have symptoms consistent with SMA? Yes ___ No ___
C. Has the diagnosis been confirmed by molecular genetic testing? Yes ___ No ___
D. Does member have biallelic pathogenic variants in the survival motor neuron gene 1 (SMN1)? Yes ___ No ___
 Other: _____
- Is member currently dependent on permanent ventilation? Yes ___ No ___
A. If member is currently dependent on permanent ventilation, please specify number of hours per day member requires ventilator support: _____
- Is Spinraza™ being prescribed by a neurologist, specialist with expertise in treatment of SMA, or an advanced care practitioner with a supervising physician who is a neurologist or specialist with expertise in treatment of SMA? Yes ___ No ___
- Has platelet count, coagulation laboratory testing, and quantitative spot urine protein testing been obtained? Yes ___ No ___
A. If yes, are levels acceptable to the prescriber? Yes ___ No ___
- Does prescriber agree to do a platelet count, coagulation test, and quantitative spot urine protein testing prior to each dose? Yes ___ No ___
- Will Spinraza™ be administered in a healthcare facility by a specialist experienced in performing lumbar punctures? Yes ___ No ___
- Has a baseline assessment been performed and documented using at least one of the following exams as functionally appropriate: Hammersmith Infant Neurological Exam (HINE), Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND), Upper Limb Module (ULM) Test, or Hammersmith Functional Motor Scale Expanded (HFMSSE)? Yes ___ No ___
A. If yes, please indicate the exam performed: _____
B. Please provide member's baseline score to exam listed above: _____

Additional Information: _____

For Continued Authorization:

- Has the member previously been approved through the SoonerCare prior authorization process? Yes ___ No ___
A. If no, please complete the initial authorization section above.
- Is member responding to the medication as demonstrated by a clinically significant improvement or maintenance of function from pre-treatment baseline status using the same exam as performed at baseline assessment? Yes ___ No ___
- Please indicate exam used to perform assessment: _____
A. Please provide member's baseline score to exam listed above: _____
B. Please provide member's current score to exam listed above: _____
- If member is currently dependent on permanent ventilation, please specify number of hours per day member requires ventilator support: _____

Additional Information: _____

Prescriber Signature: _____ **Date:** _____

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy
Pharmacy Management Consultants
Product Based Prior Authorization Unit

Fax: 1-800-224-4014
Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.